Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
Status:
Completed
Trial end date:
2019-04-10
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the pharmacokinetics (PK), tolerability, and safety
of once-weekly doses of rifapentine (RPT) and isoniazid (INH) in HIV-1-infected and
HIV-1-uninfected pregnant and postpartum women with latent tuberculosis (TB).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Hydrazine Isoniazid Pyridoxal Pyridoxine Rifampin Rifamycins Rifapentine Vitamin B 6 Vitamin B Complex Vitamins